A rollercoaster end to last week for Novo Nordisk, with fourth-quarter results and a 2026 guide that were not well received by the market, followed by news that Hims & Hers planned to sell a non-FDA-approved compounded copy of Novos newly launched Wegovy pill
Kim DS, Choi HI, Wang Y, Luo Y, Hoffer BJ, Greig NH (2017) A new treatment strategy for Parkinsons disease through the gut-brain axis: the glucagon-like peptide-1 receptor pathway
doi:10.1016/j.redox.2025.103689 12
The magic of liposomal technology lies in its ability to encapsulate both fat-soluble and water-soluble vital substances, such as vitamins
Consistent with the proposed mechanism of action, systemic application of an 2 -adrenergic receptor agonist abolished the stimulatory effect of GLP-1 in the OB on insulin secretion